Summary
The product Oxymetholone, manufactured by Hilma Biocare, underwent independent analysis to verify its quality and composition. The sample, procured and funded by Roidteam.net, a reseller of Hilma Biocare products, was analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical testing. The analysis confirmed the presence of Oxymetholone, with a measured concentration of 48.69 mg per pill, exceeding the labeled claim of 50 mg per pill by 2.62%. The product was retested twice to ensure accuracy.
The testing process began on 2 September 2022, with the sample received on 13 September 2022, and analysis completed on 15 September 2022. While the results confirm accurate dosing, independent testing of additional batches is recommended to ensure consistency. This report serves as an educational resource to support harm reduction efforts and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Hilma Biocare
- Product Name: Oxymetholone
- Active Ingredient: Oxymetholone
- Batch Number: Oxymetholone-060158
- Expiration Date: Not provided
- Delivery Method: Oral (tablet)
Sample Acquisition and Testing
- Task Number: #23830
- Testing Ordered: 2 September 2022
- Sample Received: 13 September 2022
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Roidteam.net (Reseller of Hilma Biocare)
- Analysis Paid For By: Roidteam.net
Testing Results
- Specification: 50 mg per pill (as stated on the label)
- Measured Concentration: 48.69 mg per pill
- Accuracy: 97.38% (2.62% below the label claim)
Verification Details
- Verification URL: https://janoshik.com/tests/23830_HKG2XISAL1YN
- Originally Published: https://thinksteroids.com/community/posts/3026350/
Evaluation of Reseller-Submitted Testing
This analysis highlights the accuracy of the tested product but warrants careful evaluation due to its submission and funding by Roidteam.net, a reseller of Hilma Biocare products. Resellers may select optimal batches for testing, which may not fully represent the consistency of products available to consumers. Independent validation through testing of multiple batches would strengthen reliability and consumer confidence.
Conclusion
The analysis confirms that Oxymetholone meets its labeled claim with a slight underdosing, measured at 48.69 mg per pill. This reflects strong quality control for this batch but underscores the importance of testing additional batches to verify consistency. This report is shared as part of an ongoing commitment to harm reduction and consumer education in the anabolic steroid market.
Disclaimer
This report is published for educational and harm reduction purposes. The findings pertain solely to the tested batch and do not generalize to all products under the same name. Readers are encouraged to use this information responsibly and cross-reference results with independent third-party testing where possible.
